CVS Health Corp
Q1 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +6.74%.
Did CVS Beat Earnings? Q1 2025 Results
CVS Health delivered a standout first quarter for 2025, posting adjusted EPS of $2.25 against a consensus estimate of $1.67, a beat of 34.55%, as revenue climbed 7.0% year-over-year to $94.59 billion, topping expectations by 1.31%. The single most material driver was a dramatic turnaround in the Health Care Benefits segment, where adjusted operating income surged 172.3% to $1.99 billion, fueled by $1.60 billion in favorable prior-year claims development and improved Medicare Advantage performance tied to higher star ratings. That improvement came even as CVS absorbed a $448.00 million premium deficiency reserve and announced it will exit the individual ACA exchange market in 2026, a strategic retreat that investors largely cheered given the segment's persistent margin pressure. Health Services and Pharmacy and Consumer Wellness added further momentum, with revenue gains of 7.9% and 11.1% respectively. Looking ahead, management raised its full-year 2025 adjusted EPS guidance to $6.00 to $6.20, while also lifting cash flow from operations guidance to approximately $7.00 billion, signaling confidence despite a cautious macro backdrop.
- Favorable year-over-year impact of prior-year claims development
- Improved Medicare Advantage star ratings for 2025 payment year
- Improved purchasing economics and pharmacy drug mix in Health Services
- Increased prescription volume up 4.3% YoY
- Growth in specialty pharmacy and brand inflation
- Same store prescription volume increased 6.7% YoY
“As we aim to be the most trusted health care company in America, we are driving greater care, value, and service from our integrated, industry-leading businesses. Thanks to a resolute focus on customers, our colleagues across CVS Health delivered positive results across our Health Care Benefits, Health Services and Pharmacy & Consumer Wellness segments, as we continue to build a world of better health around the 185 million consumers we are privileged to serve.”
CVS Health CEO, on the earnings call
Forward Guidance & Outlook
CVS Health raised its full-year 2025 Adjusted EPS guidance to $6.00–$6.20 (from $5.75–$6.00) and increased cash flow from operations guidance to approximately $7.0 billion (from $6.5 billion), reflecting strong performance across all business segments. GAAP diluted EPS guidance was revised to $4.23–$4.43 (from $4.58–$4.83) due to litigation and divestiture charges. The company is maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds. CVS Health will exit the individual exchange business where Aetna independently operates ACA plans for 2026.
CVS YoY Financials
CVS Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.